Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
Victoria A SanchezMegan M ShueyPaul C DinhPatrick O MonahanSophie D FossåHoward D SessoMary Eileen DolanLawrence H EinhornDavid J VaughnNeil E MartinDarren R FeldmanKurt KroenkeChunkit FungRobert D FrisinaLois B TravisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
One in three TCS with HL report clinically significant functional impairment. Follow-up of cisplatin-treated survivors should include routine assessment for HL and tinnitus. Use of the HHIA and TPFQ permit risk stratification and referral to audiologists as needed, since HL adversely affects functional status and is the single largest modifiable risk factor for cognitive decline and dementia in the general population.